Inhibitex currently has two active Phase II clinical development programs being conducted under active Investigational New Drug (IND) applications with FDA. We are studying the safety and efficacy of INX-189 for the treatment of chronic hepatitis C, and we are evaluating FV-100 for the treatment of shingles (Zoster) and shingles-associated pain.

All of the trials conducted for the INX-189 and FV-100 clinical programs will be listed on www.clinicaltrials.gov, including information regarding study design and investigative centers. Additionally, the progress of the overall INX-189 and FV-100 clinical development programs can be followed via periodic press release announcements which can be found on the Investors section on our website.